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1. INTRODUCTION 
Reactive oxygen species (ROS), as well as reactive nitrogen species (RNS), 
are products of normal cellular metabolism. ROS and RNS are well recognised for 
playing a dual role as both deleterious and beneficial species, since they can be 
either harmful or beneficial to living. Beneficial effects of ROS occur at 
low/moderate concentrations and involve physiological roles in cellular responses 
to noxia, as for example in defence against infectious agents and in the function of 
a number of cellular signalling systems. One further beneficial example of ROS at 
low/moderate concentrations is the induction of a mitogenic response. 
The harmful effect of free radicals causing potential biological damage is 
termed oxidative stress and nitrosative stress. This occurs in biological systems 
when there is an overproduction of ROS/RNS on one side and a deficiency of 
enzymatic and non-enzymatic antioxidants on the other.  
Oxidative stress results from an imbalance between the production and 
elimination of reactive oxygen and nitrogen species (ROS and RNS, respectively). 
Oxidants are generated as a result of normal intracellular metabolism in 
mitochondria and peroxisomes, as well as from a variety of cytosolic enzyme 
systems. In addition, a number of external agents can trigger ROS production. A 
sophisticated enzymatic and non-enzymatic antioxidant defence system counteracts 
and regulates overall ROS levels to maintain physiological homeostasis. Lowering 
ROS levels below the homeostatic set point may interrupt the physiological role of 
oxidants in cellular proliferation and host defence. Similarly, increased ROS may 
also be detrimental and lead to cell death or to an acceleration in ageing and age-
related diseases as shown below (Finkel, T. Holbrook, N.J. Nature 408, 239-247, 
2000). 
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Most disease states are accompanied by oxidative stress which contributes to 
tissue injury. Mechanism of oxidative stress-induced tissue injury includes 
oxidative damage to proteins, lipids and DNA culminating in cell dysfunction, 
apoptosis or necrosis depending on the intensity of oxidative stimuli. In addition to 
cumulative damage to macromolecules, oxidative stress also triggers tightly 
regulated signalling pathways mediating cell dysfunction, apoptosis and necrosis. 
These pathways include but are not limited to MAP kinases, apoptotic signal 
regulated kinases, and poly (ADP-ribose) polymerase-1 (PARP-1). PARP-1 is a 
nuclear enzyme activated by DNA breakage. Activated PARP-1 tags the proteins at 
the site of DNA damage with an NAD+-derived biopolymer, poly(ADP-ribose) 
(PAR) and thus facilitates DNA repair. However, during severe oxidative stress, 
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PARP-1 contributes to necrotic cell death via depletion of its substrate NAD+ and 
consequently ATP and in some cell types by activating the cell death pathway 
mediated by apoptosis-inducing factor.  
Oxidative stress-induced cell death and the role of the above signalling 
pathways have been demonstrated in various life threatening conditions such as 
neurodegenerative disorders, myocardial infarction, stroke, different forms of 
shock and ischemia–reperfusion injury of different organs. A wide array of 
approaches has been devised to combat these diseases and many of these efforts 
aim at preserving cellular integrity. Cytoprotective compounds such as 
antioxidants, PARP inhibitors, JNK inhibitors, potassium channel openers have 
been shown to effectively protect tissues from oxidative tissue injury. 
Nonetheless, successful treatment of oxidative stress-related diseases 
continues to pose challenges for physicians and requires the development of novel 
treatment modalities. The aim of the current study was to identify cytoprotective 
compounds with the potential to provide therapeutic benefit in conditions 
associated with tissue injury. 
Doxorubicin is an anthracycline compound originally isolated from bacteria 
of the Streptomyces genus and used extensively for the treatment of various types 
of cancer. Acute leukaemia, Hodgkin and non-Hodgkin lymphomas, osteosarcoma, 
Ewing sarcoma, breast cancer, neuroblastoma, small cell lung cancer respond well 
to doxorubicin monotherapy or combination therapy. Even though doxorubicin and 
other anthracycline compounds such as daunorubicin have been used by 
oncologists for more than four decades, their mechanism of action is still not fully 
understood. Inhibition of topoisomerase II, generation of reactive oxygen species, 
DNA intercalation and triggering a signalling cascade that involves increased 
ceramide production, cleavage of the ER membrane protein CREB3L1, nuclear 
translocation of the N-terminal fragment of this protein and transcriptional 
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activation of genes that inhibit cell proliferation have been suggested to be 
responsible for the antitumor effect of anthracyclins. 
The clinical use of doxorubicin is limited mainly by its severe cardiotoxic 
effect, which may lead to irreversible cardiomyopathy and heart failure. Incidence 
of heart failure shows close correlation with the cumulative dose of the drug. 
Cardiotoxicity is indicated by morphological alterations (myofibrillar disarray and 
vacuolization) as observed in cardiac biopsy specimens. Moreover, leakage of 
troponin can also be detected in the peripheral blood and shows positive correlation 
with the intensity of heart damage.  
The mechanism of doxorubicin cardiotoxicity is complex and is closely 
linked to production of reactive oxygen species. These form in direct electron 
exchange between the oxygen molecule and the anthracycline’s quinone moiety 
and can also be produced in redox cycling of doxorubicin-iron complexes. The 
significance of ROS signalling in doxorubicin-induced heart failure is supported by 
a number of animal experiments demonstrating the effectiveness of a 
ferroporphyrine antioxidant a vitamin E prodrug or a poly(ADP-ribose) 
polymerase (PARP) inhibitor in preventing or suppressing the cardiotoxic effect of 
doxorubicin. In recent years topoisomerase 2 has emerged as a central mediator 
of doxorubicin-induced cardiac injury. While topoisomerase 2 (expressed mostly 
in proliferating cells) is considered as the primary target of doxorubicin in tumour 
cells, topoisomerase 2 (expressed by quiescent cells) has been made responsible 
for suppression of antioxidant enzyme expression, inhibition of mitochondrial 
biogenesis, activation of p53 and p53-mediated apoptosis with all of these cellular 
events implicated in doxorubicin-induced heart failure. 
Despite our increasing knowledge on the mechanism of doxorubicin-induced 
heart injury, it still represent an unsolved medical problem necessitating more 
mechanistic studies as well as the development of novel agents for the prevention 
of the side effect of anthracyclins.  
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2. OBJECTIVES 
The principal aim of the thesis was to establish the high throughput screening 
(HTS) methodology in the setting of an academic laboratory in order to screen 
compound libraries and to identify novel cytoprotective agents  
The specific aims were as follows: 
1. To develop in vitro cell-based HTS assays for the screening of potentially 
cytoprotective and or antioxidant molecules.  
2. To validate the HTS assays by well-established manual methods. 
3. Screening the in-house library   (about 2600 molecules) for novel 
cytoprotective compounds. 
4. To develop a screening strategy for the identification of potentially 
cardioprotective compounds with the capacity to prevent doxorubicin-
induced cardiomyocyte injury. 
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3. MATERIALS AND METHODS 
Materials 
The compound library of the University of Debrecen (UDM) was established 
and maintained by the Department of Organic Chemistry. The library contains 
about 2600 compounds of high (at least 95%) purity with the unique feature of the 
great number of oxygen heterocycles and their precursors. The compounds were 
obtained by traditional synthetic methods and show high diversity.  
Chembridge compound library 10.000 (San Diego, CA, USA) and 
doxorubicin were purchased from Teva (Debrecen, Hungary). The sources of other 
chemicals, assay kits and antibodies are given in the papers published by us (see 
Appendix items 1 & 2). 
 
Cell lines 
H9C2 cells were cultured in DMEM (10% FBS and 2mM glutamine, 5g/L 
glucose). A549 cell line was cultured in RPMI 1640 medium supplemented with 
10% FBS and 2mM glutamine. SAOS-2 cell line was cultured in DMEM (10% 
FBS and 2mM glutamine, 1g/L glucose). 
  
Primary neonatal rat cardiomyocyte culture  
Primary neonatal cardiomyocyte culture was prepared from 1-3 days old 
Wistar rats. Pups were killed by cervical dislocation, and then the hearts were 
harvested and rinsed in ice-cold PBS buffer. The ventricles were then chopped and 
digested in trypsin to increase the number of cardiomyoblasts in the cell 
suspension. Then cells were plated and maintained in a humidified incubator 
(37ºC, 95% O2 and 5% CO2). After 24 hours, the medium was changed to DMEM 
containing 1% FBS to help cardiomyoblast differentiation.  
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MTT viability assay (HTS version) 
Cells (7x103/well) were plated to 96-well plates one day before the treatment. 
Compounds of the library were given to the plates with a Tecan Freedom EVO 
liquid handling robot (100 nL/well) to reach 10 M final concentration. After 30 
min incubation at 37°C, cells were further treated with the respective protocols. 
Finally MTT solution was added to the samples, supernatants were aspirated and 
the assay was performed with a Thermo Multiskan reader at 540nm.  
 
Cytotoxicity assay 
Cytotoxicity of the test compounds was determined with resazurin assay as 
described above. Cells were incubated with the compounds at different 
concentrations for 24 h and then the resazurin method was used to determine the 
viability of the cells.  
 
Morphology-based cytotoxicity assay 
Cells were treated with the hit compounds of the screening, in the final 
concentration of 12 M. After 30 min incubation at 37°C, cells were treated with 
doxorubicin (300 ng/mL final concentration). Samples were incubated for 24 hours 
at 37°C. Cell culture medium was changed to Coomassie staining solution and 
incubated for 20 minutes. Samples were washed and dried. Photos were taken and 
image analysis performed with Tscratch software was used to determine the size of 
cell-covered areas. 
 
ABTS decolourization assay  
Preparation of ABTS was performed as described [10]. Assays were done in 
96-well plates in triplicates. Samples were incubated at RT for 30 minutes. 
Absorbance was measured with Victor V3 multi-label reader (405 nm). Antioxidant 
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activity was expressed as the percentage of control samples and was compared to 
the effect of Trolox.  
 
Cupric ion reducing antioxidant capacity (CUPRAC) assay 
Measures total antioxidant capacity based on reduction of copper(II) to 
copper(I). Trolox was used as positive control and the assays were performed in 
96-well microplates. 
 
Caspase-3 activity measurement 
Apoptosis is mediated by a cascade of proteolytic enzymes known as 
cysteine proteases or caspases. We have used fluorescent substrate-based caspase-3 
assay kit for microplates.  
 
LDH release assay 
Cells release LDH after tissue damage since LDH is a fairly stable enzyme, it 
has been widely used to evaluate the presence of damage and toxicity of cells. In 
the assay LDH reduces NAD to NADH, which is specifically detected by 
colorimetric (450 nm) assay.  
 
PARP activity assay (DELFIA) 
PARP inhibitory activity of the compounds was tested in DELFIA assay 
(Dissociation-Enhanced Lanthanide Fluorescent Immunoassay). 96-well 
polystyrene plates were coated with 0.1% purified histone protein and were 
incubated overnight at 40C. PARP DELFIA assay was performed according to the 
manufacturer’s instructions. PJ34 was used as positive control. Measurements were 
done with a Perkin Elmer Victor V3 multilabel reader. 
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Calcein-based viability assay 
To further confirm the cardioprotective effect of the lead compound (EODB) 
against doxorubicin induced cellular damage, two days old primary neonatal 
cardiomyocyte cultures were pre-treated with 5-25 µM EODB for 30 minutes 
followed by 300 ng/mL doxorubicin treatment for 24 hr. At the end of the protocol 
viability was determined by calcein assay. In living cells, the cell-permeable 
calcein AM (nonfluorescent) is hydrolysed by intracellular esterases to calcein 
(green-fluorescent). Fluorescence intensity was measured using 490-nm excitation 
and 520-nm emission filters. 
 
Detection of MAP kinase activation by Western blotting 
MAP kinases and their phosphorylated active forms were detected by 
Western blotting using antibodies for the respective forms of proteins. 
 
Statistical analysis 
All experiments were performed three times on different days. Analysis of 
variance followed by Bonferroni’s test was applied for statistical analysis and for 
the determination of significance with p < 0.05 considered as significant. Analysis 
of variance for Chembridge molecular library was performed by one way ANOVA 
followed by Tukey's test for statistical analysis and for the determination of 
significance with P < 0.05 considered as significant. 
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4. RESULTS AND DISCUSSION 
 
HTS screening and validation 
By screening the compound library of the University of Debrecen in a 
resazurin reduction-based cytotoxicity assay, out of 1863 molecules we identified 
29 cytoprotective compounds protecting Jurkat cells from hydrogen peroxide-
induced toxicity. In the antioxidant assay based on ABTS radical scavenging, 123 
compounds were found to have antioxidant properties. To validate our HTS data 
on antioxidant effects, we also worked out a manual antioxidant assay with the 
cytoprotective compounds which confirmed the results of the screen. Out of the 29 
cytoprotective compounds, 11 were found to possess antioxidant activity (ABTS 
radical scavenging). 
 
Identifying PARP inhibitory cytoprotective compounds 
 In a cell-free enzyme assay two compounds of the UDM molecular library 
showed PARP inhibitory activity.  In order to confirm this inhibitory effect in a 
cellular system we have pre-treated Jurkat and A549 cells with these two 
compounds and then treated the cells with hydrogen peroxide to stimulate PARP 
activation and PAR synthesis. Hydrogen peroxide treatment leads to significant 
PARP activation as indicated by the appearance of PAR polymer as detected in 
Western blots and immunocytochemistry. 
 
Dibenzoylmethane (DBM) derivatives as novel cytoprotective agents 
After retesting our hit compounds in MTT viability assay, and in two 
additional antioxidant assays (CUPRAC assay and Amplex red assay) DBM 
derivatives emerged as novel cytoprotective agents with no hydrogen peroxide-
specific antioxidant effects. DBM derivatives did not prevent caspase-mediated-
apoptotic death in hydrogen peroxide-treated cells, nor have they inhibited 
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hydrogen peroxide-induced mitochondrial depolarization as would be expected 
from an antioxidant molecule.  
We have also investigated whether any of the MAP kinases [extracellular 
signal regulated kinase 1 and 2 (ERK1/2), p38 and c-Jun N-terminal kinase, JNK] 
are targeted by the cytoprotective DBM compounds. We found that hydrogen 
peroxide activated ERK1/2 and p38 but not JNK as indicated by Western blot 
detection of the phosphorylated active form of these kinases. The DBM derivatives 
inhibited ERK1/2 activation but had no effect on the phosphorylation of p38. 
These data suggest that these DBM derivatives primarily target the necrotic cell 
death pathway via inhibition of ERK1/2 kinases. 
DBM proved to be a promising chemopreventive agent for different types of 
cancer (e.g. colon, breast and skin cancers) by mediating the induction of phase II 
and phase I detoxification enzymes. In gastrointestinal cancers, dietary DBM 
administration decreased the levels of prostaglandin E2 or leukotriene B4 and 
inhibited cell survival and growth-related signalling pathways. An antiproliferative 
effect of DBM has also been reported. Moreover, antiinflammatory activity of a 
DBM analogue was found to be comparable to aspirin in TPA induced ear oedema. 
 
Screening for cardioprotective compounds protecting from doxorubicin 
toxicity 
We have screened the Chembridge Diverset Compound library consisting of 
9680 compounds. For this we used H9C2 rat cardiomyocytes and determined cell 
viability 24h after doxorubicin treatment. Compounds showing at least 20% 
cardioprotection were considered potentially cardioprotective. Fifteen compounds 
met this criteria and were used in subsequent experiments. According to our 
experience a drawback of MTT-based or similar dehydrogenase activity-based 
viability assays is the frequent occurrence of false positive hits. Therefore we have 
analysed the morphology of cells after doxorubicin treatment and retested the 15 
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primary hit compounds. By determining the surface area occupied by living cells 
we have detected decreased viability in doxorubicin-treated samples. Out of the 15 
compounds retested only compound #10 appeared to convincingly exert protective 
effect in doxorubicin-treated H9C2 cells. This compound is 3-[2-(4-ethylphenyl)-
2-oxoethyl]-1,2-dimethyl-1H-3,1-benzimidazol-3-ium-bromide hereafter referred 
to as EODB. 
Structural analysis of EODB may also give hints to explain both the 
protective effect of the compound and its side effects. EODB contains a 
benzimidazole moiety which may be linked to some of these effects. 
Benzimidazole derivatives represent a pharmacologically active family of agents 
with demonstrated antiviral, antimicrobial and antidiabetic effects. Moreover, 
compounds with a benzimidazole scaffold also have demonstrated antitumor effect 
via inhibition of topoisomerases.  
On the one hand this may be important for explaining both the doxorubicin-
protective effect and the toxic effect of EODB on tumour cell lines. EODB did not 
interfere with the antitumor effect of doxorubicin in the two tumour cell line we 
tested. In fact, it also proved cytotoxic in the absence of doxorubicin. We have not 
observed toxicity on H9C2 cells but in primary rat cardiomyocytes the toxicity 
may have contributed to the limited though significant protective effect of EODB. 
 
EODB protects H9C2 cells both from apoptotic and from necrotic cell death. 
We have further characterized the cytoprotective effect of EODB. It is well-
known that doxorubicin induced cell death has both apoptotic and necrotic 
features. We have determined cellular caspases-3 activity and release of LDL to 
assess apoptotic and necrotic cell death, respectively. Pre-treatment of the cells 
with EODB inhibited both caspases-3 activation and LDH release indicating 
protection from both apoptotic and necrotic cell death.  
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EODB protects primary rat cardiomyocytes from doxorubicin-induced 
damage   
Cell-based screening programs typically utilize immortalized cell lines due to 
relatively cheap culture, easy manipulation (e.g. gene silencing) and availability of 
high number of cells. However, the spontaneous or induced mutations that were 
required for immortalization, may alter the biological behaviour and responses of 
these cell. Therefore we have also investigated the effect of EODB on primary rat 
cardiomyocytes. We found that at 12 M concentration EODB provided a 
significant (18 %) protection from doxorubicin-induced toxicity. 
 
EODB lacks antioxidant activity 
Since generation of ROS and RNS is considered as an important event in 
doxorubicin-induced cardiac damage and experimental compounds providing 
protection against doxorubicin-induced cardiotoxicity possess antioxidant effect 
we set out to determine whether or not EODB can scavenge radicals. First we 
tested the compound in parallel with Trolox (positive control) in ABTS 
decolourisation assay but it had no radical scavenging effect. In the CUPRAC 
assay which detects reducing activity the compound also showed no such effect. 
Thus it appears that the cytoprotective effect of EODB is not due to an antioxidant 
effect. 
Thus it is quite likely that the cardioprotective effect of EODB is indirect and 
may interfere with damage-signalling pathways. In the doxorubicin-induced 
cardiotoxicity model, the lack of antioxidant effect is not incompatible with 
cardioprotection as indicated by the protective effect of inhibitors of poly(ADP-
ribosyl)ation, topoisomerase or angiotensin type-1 receptor. EODB may also target 
a step in one of the many cell death pathways. Our data demonstrated that it 
inhibits both apoptotic and necrotic cell death suggesting that it more likely 
interferes with a proximal event of damage-signalling rather than specifically 
16 
 
targeting one particular cell death pathway. In fact such “indirect” effects may bear 
higher clinical relevance than direct radical scavenging, because, despite promising 
preclinical data, antioxidant approaches (e.g. N-acetyl cysteine or iron chelation) 
were not effective in humans. 
 
EODB does not interfere with the antitumor effect of doxorubicin 
For a potential drug candidate to be used to protect cardiomyocytes in 
doxorubicin-treated cancer patients, it is important not to compromise the 
antitumor effect of doxorubicin. Doxorubicin is used in the treatment of different 
kinds of tumours including cancers of lung and bone origin. Therefore we tested 
whether or not EODB affects the cytotoxic effect of doxorubicin in A549 lung 
epithelial carcinoma and SAOS-2 osteosarcoma cell lines. We found that EODB 
did not interfere with the tumour cell killing activity of doxorubicin.  Interestingly, 
EODB alone (without doxorubicin) was toxic to these cancer cell lines; an effect 
we have not observed either in H9C2 cell cultures. 
In summary, our experiments proved the viability of the cell-based HTS 
approach for the identification of doxorubicin protective compounds. EODB 
protected both H9C2 cells and rat primary cardiomyocytes from doxorubicin-
induced toxicity without hampering the anti-tumour effect of doxorubicin. Through 
structure optimization EODB may serve as a template for the development of 
compounds protecting heart cells from doxorubicin-induced toxicity. Further 
investigations are needed to identify the exact molecular target of this promising 
drug candidate. 
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5. SUMMARY 
Screening of a small in-house library (University of Debrecen) of 1863 
compounds identified 29 compounds that protected Jurkat cells from hydrogen 
peroxide-induced cytotoxicity. From the cytoprotective compounds eleven proved 
to possess antioxidant activity (ABTS radical scavenger effect) and two were 
found to inhibit poly(ADPribosyl)-ation (PARylation), a cytotoxic pathway 
operating in severely injured cells. Four cytoprotective dibenzoyl-methane (DBM) 
derivatives were investigated in more detail as they did not scavenge hydrogen 
peroxide nor did they inhibit PARylation.  
DBM compounds protected cells from necrotic cell death while caspase 
activation, a parameter of apoptotic cell death was not affected. Hydrogen peroxide 
activated extracellular signal regulated kinase (ERK1/2) and p38 MAP kinases but 
not c-Jun N-terminal kinase (JNK). The cytoprotective DBMs suppressed the 
activation of Erk1/2 but not that of p38. 
Cytoprotection was confirmed in another cell type (A549 lung epithelial 
cells), indicating that the cytoprotective effect is not cell type specific. In 
conclusion we identified DBM analogues as a novel class of cytoprotective 
compounds inhibiting ERK1/2 kinase and protecting from necrotic cell death by a 
mechanism independent of poly(ADP-ribose) polymerase inhibition. 
Anthracyclins are effective anti-tumour agents. One of the most commonly 
used anthracyclins is doxorubicin, which can be successfully used to treat a diverse 
spectrum of tumours. Application of these drugs is limited mainly by their 
cardiotoxic effect, which is determined by a lifetime cumulative dose. As the 
processes that are responsible for tumour chemotherapy and cardiotoxicity are 
different, this may give a hope for eliminating the side effect without affecting the 
anti-tumour effect.  
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In our recent work, 10 000 compounds of the Chembridge’s Diverset 
compound library were screened to identify compounds that can protect H9C2 rat 
cardiomyocytes against doxorubicin-induced cell death. An MTT-based high 
throughput viability screening was performed followed by retesting of the hit 
compounds in a morphology-based assay. The most effective compound proved 
protective in DOX-treated primary rat cardiomyocytes and was further 
characterized to demonstrate that it significantly decreased doxorubicin-induced 
apoptotic and necrotic cell death without having a radical scavenging effect or 
interfering with the antitumor effect of DOX. This benzimidazole compound may 
lead – through further optimalization – to the development of a drug candidate 
protecting the heart from DOX-induced injury. 
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